Article - 07/02/2008 New life sciences centre in Ulm The new Life Science Centre will house eleven interfaculty research groups dealing with aspects of tissue regeneration. The state of Baden-Württemberg and the University both expressed their high expectations for the centre at the official opening.https:////www.gesundheitsindustrie-bw.de/en/article/news/new-life-sciences-centre-in-ulm
Press release - 16/10/2012 Merck Serono Launches € 1 Million Research Grant for Multiple Sclerosis Innovation Merck Serono, a division of Merck, Darmstadt, Germany, announced on 10th Oktober 2012 during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Lyon, France, that the company has initiated a new global research award to improve understanding of multiple sclerosis for the ultimate benefit of patients.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/merck-serono-launches-1-million-research-grant-for-multiple-sclerosis-innovation
Article - 14/04/2014 New insights into apoptotic signalling networks Apoptosis, i.e. programmed cell death, is a precisely regulated process that leads to the elimination of surplus or damaged cells. The proteins of the Bcl-2 family play a key role in apoptosis. However, their complex interactions are not yet known in detail. A group of researchers from Germany, Austria and Switzerland is now trying to get to the bottom of this issue. Coordinated by the University of Konstanz, the researchers are jointly…https:////www.gesundheitsindustrie-bw.de/en/article/news/new-insights-into-apoptotic-signalling-networks
Dossier - 14/11/2011 The European Nutrition and Health Claims Regulation - an interesting recipe The EU Nutrition and Health Claims Regulation applies to all nutrition and health claims made in commercial communications, including the advertising and labelling of food and promotional campaigns. While the information related to nutrition is now clear, the list of permitted health claims is still under development.https:////www.gesundheitsindustrie-bw.de/en/article/dossier/the-european-nutrition-and-health-claims-regulation-an-interesting-recipe
Vaccine development - 02/11/2015 A new vaccine could prevent influenza epidemics Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…https:////www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
Article - 29/01/2008 Breakthrough for glycomics New databases and bioinformatic tools provide the field of glycomics with a solid basis for dynamic development in molecular biology and medicine. Willi von der Lieth a researcher from Heidelberg was an important pioneer of glyco-bioinformatics. His sudden death is a great loss for this new scientific field.https:////www.gesundheitsindustrie-bw.de/en/article/news/breakthrough-for-glycomics
Article - 21/03/2016 Shock wave therapy gives hope to many men Although the approval of vasodilatory drugs made available an effective medicine for treating erectile dysfunction, not all men respond to this type of treatment. MTS Medical UG from Konstanz has developed a therapeutic device that means that these men can now get help too. What's more, the device has no adverse health effects.https:////www.gesundheitsindustrie-bw.de/en/article/news/shock-wave-therapy-gives-hope-to-many-men
Article - 14/02/2011 Affimed’s novel TandAb® antibodies enter clinical development phase With the initiation in October 2010 of a Phase I (“first in man”) study of the tetravalent, bispecific antibody AFM13 based on its proprietary TandAb® technology, Heidelberg-based Affimed Therapeutics AG has become a clinical drug development company. https:////www.gesundheitsindustrie-bw.de/en/article/news/affimed-s-novel-tandab-antibodies-enter-clinical-development-phase
Dossier - 30/08/2010 Disease prevention through better diagnostics “Classical treatment approaches are not the only way to ensure good health, rehabilitation and care. In fact, it is envisaged that more effective prevention will contribute to halting the development of diseases and maintaining good health. Prevention is designed to prevent health risks and diseases, make them less likely and delay their onset.” (Declaration of the German government; Official Records of Parliament 17/845, 26th February 2010) https:////www.gesundheitsindustrie-bw.de/en/article/dossier/disease-prevention-through-better-diagnostics
Press release - 22/04/2010 Biotechnology is a driver of economic growth The latest economic figures on biotechnology were presented at the German Biotechnology Days held in Berlin on 21st and 22nd April 2010. The figures show that German biotechnology companies have not lost their innovation power despite the global financial crisis. In 2009 the companies RD expenditures of around one billion euros remained at a similar high level to the previous year. The biotechnology industry is creating new jobs despite the…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/biotechnology-is-a-driver-of-economic-growth
Article - 12/06/2010 Reliable evidence of efficacy using skin models and assays In the molecular biology laboratory at the Albstadt-Sigmaringen University of Applied Sciences a team led by Prof. Dr. Jörg Bergemann is developing and optimising assays that enable the quantitative determination of DNA damage and the investigation of repair mechanisms. The researchers exclusively use in vitro test systems. Using tissue engineering methods the researchers are developing a skin model for pharmacological efficacy and…https:////www.gesundheitsindustrie-bw.de/en/article/news/reliable-evidence-of-efficacy-using-skin-models-and-assays
Press release - 10/01/2012 Apogenix receives additional 2.3 million Euros BMBF grant as partner of the biotech cluster Rhine-Neckar The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-receives-additional-2-3-million-euros-bmbf-grant-as-partner-of-the-biotech-cluster-rhine-ne
Article - 15/12/2014 Heart muscle cell 1.0 and 2.0 – two epigenetic programmes in one cell All the cells in an organism have to adapt to changing requirements as they develop and grow - including muscle cells in the heart. Crucial to this process are the cells’ growth in size and epigenetic factors that play a role in modulating the expression of various genes. The role of epigenetics in cancer development has been the focus of research for quite some time. The question is, what role do epigenetic factors play in the development of the…https:////www.gesundheitsindustrie-bw.de/en/article/news/heart-muscle-cell-1-0-and-2-0-two-epigenetic-programmes-in-one-cell
Press release - 01/04/2015 Migrating immune cells promote nerve cell demise in the brain The slow death of dopamine-producing nerve cells in a certain region of the brain is the principal cause underlying Parkinson's disease. In mice, it is possible to simulate the symptoms of this disease using a substance that selectively kills dopamine-producing neurons. Scientists from the German Cancer Research Center (DKFZ) have now shown for the first time in mouse experiments that after this treatment, cells of the peripheral immune…https:////www.gesundheitsindustrie-bw.de/en/article/press-release/migrating-immune-cells-promote-nerve-cell-demise-in-the-brain
Article - 21/03/2011 Immunotherapy: the rocky road to clinical application Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…https:////www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
Article - 15/10/2012 Nobel Prize for the reprogramming of cells The Nobel Prize in Physiology or Medicine 2012 was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent, i.e. immature cells capable of developing into all tissues of the body. This finding is of revolutionary importance for the field of medicine.https:////www.gesundheitsindustrie-bw.de/en/article/news/nobel-prize-for-the-reprogramming-of-cells
Article - 25/11/2013 Elisa May: a sharp, microscopic look at DNA damage DNA damage is part of our everyday life. Every day, tens of thousands of DNA single-strand breaks occur in every cell, but we have a variety of sophisticated genome maintenance mechanisms to protect ourselves against such problems. However, serious diseases can result in cases where the cellular repair system fails. Amongst other things, there is a close relationship between the failure of DNA repair mechanisms and the development of cancer.…https:////www.gesundheitsindustrie-bw.de/en/article/news/elisa-may-a-sharp-microscopic-look-at-dna-damage
Article - 21/01/2013 Early warning signals of ageing in stem cells The large international project SyStemAge is specifically focused on the role of stem cells in ageing and age-related diseases. Coordinated by the European Molecular Biology Laboratory and the Heidelberg University Hospital the SyStemAge consortium seeks to identify the causes and molecular pathways associated with the processes of ageing on the stem-cell level as well as developing novel strategies for the early treatment of age-related…https:////www.gesundheitsindustrie-bw.de/en/article/news/early-warning-signals-of-ageing-in-stem-cells
Article - 16/04/2012 DNA recombination for targeted plant breeding Did evolution invent games of chance? During the development of sperm and egg cells, maternal and paternal genes are mixed at random, thus giving rise to new combinations of traits. What are the molecular mechanisms of this process known as DNA recombination? How can it be used to breed plants with higher yields? Prof. Dr. Holger Puchta and his team at the Karlsruhe Institute of Technology (KIT) are investigating the processes associated with the…https:////www.gesundheitsindustrie-bw.de/en/article/news/dna-recombination-for-targeted-plant-breeding
Article - 24/10/2009 Molecular switches for gene expression in the embryo Prof. Dr. Andreas Hecht and his team at the University of Freiburg are investigating one of seven known fundamental signalling systems that are involved in almost all embryonic development processes and that determine the fate of cells. The scientists are mainly interested in gaining insights into why the same molecules initiate different genetic programmes and hence development pathways depending on the cell type where they have their effect.https:////www.gesundheitsindustrie-bw.de/en/article/news/molecular-switches-for-gene-expression-in-the-embryo
Article - 21/06/2008 Wanting children without risk In Germany one couple in ten is unable to conceive naturally. There are a number of different in vitro fertilisation methods available for those who wish to have children. However the potential risks to the child are still unknown.https:////www.gesundheitsindustrie-bw.de/en/article/news/wanting-children-without-risk
Press release - 30/07/2009 Boehringer Ingelheim set to outpace the market again After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again
Press release - 30/04/2009 Prize for more efficient radiotherapy for leukaemia Peter Kletting’s model can be used to irradiate the tumour cells of leukaemia patients more accurately, reduce potential side effects and increase the chances of therapeutic success. The scientist from the Department of Nuclear Medicine at the University Hospital of Ulm has been awarded the Society for Nuclear Medicine Covidien Award that comes with a purse of 7,500 euros. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/prize-for-more-efficient-radiotherapy-for-leukaemia
Big Data - 13/03/2018 “More data does not automatically imply more knowledge“ In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted. https:////www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge
Article - 17/09/2012 Biochemisty and the assembly of ammonium machines Researchers who intend to build enzymes in the laboratory need detailed knowledge about the function of the respective enzymes. Using modern biochemistry methods researchers led by Prof. Dr. Oliver Einsle from the University of Freiburg have in the last few years clarified the atomic structure of a complex bacterial protein that converts atmospheric nitrogen into a form that can be readily used by other organisms. The researchers have recently…https:////www.gesundheitsindustrie-bw.de/en/article/news/biochemisty-and-the-assembly-of-ammonium-machines